Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment.
B7-H3
anticancer agents
immunotherapy
pediatric solid tumors
targeted therapy
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
11 Apr 2023
11 Apr 2023
Historique:
received:
14
03
2023
revised:
05
04
2023
accepted:
07
04
2023
medline:
1
5
2023
pubmed:
28
4
2023
entrez:
28
4
2023
Statut:
epublish
Résumé
Recent scientific data recognize the B7-H3 checkpoint molecule as a potential target for immunotherapy of pediatric solid tumors (PSTs). B7-H3 is highly expressed in extracranial PSTs such as neuroblastoma, rhabdomyosarcoma, nephroblastoma, osteosarcoma, and Ewing sarcoma, whereas its expression is absent or very low in normal tissues and organs. The influence of B7-H3 on the biological behavior of malignant solid neoplasms of childhood is expressed through different molecular mechanisms, including stimulation of immune evasion and tumor invasion, and cell-cycle disruption. It has been shown that B7-H3 knockdown decreased tumor cell proliferation and migration, suppressed tumor growth, and enhanced anti-tumor immune response in some pediatric solid cancers. Antibody-drug conjugates targeting B7-H3 exhibited profound anti-tumor effects against preclinical models of pediatric solid malignancies. Moreover, B7-H3-targeting chimeric antigen receptor (CAR)-T cells demonstrated significant in vivo activity against different xenograft models of neuroblastoma, Ewing sarcoma, and osteosarcoma. Finally, clinical studies demonstrated the potent anti-tumor activity of B7-H3-targeting antibody-radioimmunoconjugates in metastatic neuroblastoma. This review summarizes the established data from various PST-related studies, including in vitro, in vivo, and clinical research, and explains all the benefits and potential obstacles of targeting B7-H3 by novel immunotherapeutic agents designed to treat malignant extracranial solid tumors of childhood.
Identifiants
pubmed: 37110590
pii: molecules28083356
doi: 10.3390/molecules28083356
pmc: PMC10145344
pii:
doi:
Substances chimiques
B7 Antigens
0
Immunoconjugates
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Mod Pathol. 2010 Aug;23(8):1104-12
pubmed: 20495537
Mol Ther Oncolytics. 2020 Jun 23;18:202-214
pubmed: 32728609
Mol Ther Oncolytics. 2022 Aug 25;26:429-443
pubmed: 36159778
Curr Opin Pediatr. 2020 Feb;32(1):48-56
pubmed: 31815779
N Biotechnol. 2011 Sep;28(5):518-29
pubmed: 21473941
Oncogene. 2019 Jan;38(1):88-102
pubmed: 30082909
PLoS One. 2014 Jan 29;9(1):e87769
pubmed: 24489959
Am J Cancer Res. 2015 Apr 15;5(5):1602-9
pubmed: 26175931
Cells. 2020 May 09;9(5):
pubmed: 32397414
Cell Death Dis. 2020 Oct 3;11(10):824
pubmed: 33011740
Front Immunol. 2021 Oct 05;12:757047
pubmed: 34675936
Ann Med Surg (Lond). 2014 Sep 11;3(4):113-6
pubmed: 25568796
Front Immunol. 2021 Jun 15;12:691741
pubmed: 34211478
Front Immunol. 2021 Jul 19;12:701006
pubmed: 34349762
Cancers (Basel). 2022 Dec 19;14(24):
pubmed: 36551734
Oncol Rep. 2015 Jan;33(1):274-82
pubmed: 25370943
Front Immunol. 2021 Sep 10;12:707211
pubmed: 34566963
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Neuro Oncol. 2021 Jun 1;23(6):999-1011
pubmed: 33320196
Cancer Immunol Res. 2020 Feb;8(2):161-166
pubmed: 32015013
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Front Oncol. 2022 Mar 22;12:832765
pubmed: 35392217
Cancer Res. 2005 Nov 1;65(21):9891-8
pubmed: 16267013
Mol Ther Oncolytics. 2020 Apr 07;17:180-189
pubmed: 32346608
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
Oncotarget. 2013 Mar;4(3):433-45
pubmed: 23531921
Oncogene. 2006 Aug 28;25(38):5220-7
pubmed: 16936740
Mol Ther Oncolytics. 2019 Nov 29;16:41-52
pubmed: 31930165
Prostate Cancer Prostatic Dis. 2021 Sep;24(3):767-774
pubmed: 33558663
Medicine (Baltimore). 2019 Feb;98(8):e14663
pubmed: 30813210
Nat Rev Immunol. 2014 Jun;14(6):361-76
pubmed: 24854588
Adv Drug Deliv Rev. 2015 Jun 29;87:3-14
pubmed: 25979468
Mol Med Rep. 2019 May;19(5):4315-4325
pubmed: 30942404
J Clin Oncol. 2020 Dec 20;38(36):4283-4291
pubmed: 33119478
Nat Rev Cancer. 2006 Apr;6(4):259-69
pubmed: 16557279
Am J Transl Res. 2015 Dec 15;7(12):2646-60
pubmed: 26885263
J Immunother Cancer. 2021 Aug;9(8):
pubmed: 34417325
Tumour Biol. 2016 Mar;37(3):2961-71
pubmed: 26411671
Mol Cancer. 2020 Dec 14;19(1):172
pubmed: 33317550
Clin Transl Oncol. 2022 Jun;24(6):1204-1208
pubmed: 34988920
Cancer Discov. 2023 Jan 9;13(1):114-131
pubmed: 36259971
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Clin Cancer Res. 2017 Jan 15;23(2):342-350
pubmed: 27836863
J Clin Invest. 2020 Jul 1;130(7):3391-3402
pubmed: 32538896
PLoS One. 2013 Aug 05;8(8):e70689
pubmed: 23940627
J Hematol Oncol. 2022 Nov 12;15(1):165
pubmed: 36371226
Cancer Res. 2009 Aug 1;69(15):6275-81
pubmed: 19584290
Cancer Metastasis Rev. 2009 Dec;28(3-4):369-78
pubmed: 20012925
J Clin Invest. 2022 Aug 15;132(16):
pubmed: 35852863
J Genet Genomics. 2012 Oct 20;39(10):535-43
pubmed: 23089363
Int J Clin Exp Pathol. 2015 Nov 01;8(11):13987-95
pubmed: 26823710
Cells. 2022 Apr 06;11(7):
pubmed: 35406801
Mol Med Rep. 2015 Oct;12(4):5455-60
pubmed: 26151358
Int J Biol Sci. 2020 Mar 25;16(11):1767-1773
pubmed: 32398947
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Int J Cancer. 2012 May 15;130(10):2282-90
pubmed: 21671471
Arthritis Res. 2002;4 Suppl 3:S39-49
pubmed: 12110122
Oncotarget. 2016 Feb 9;7(6):6891-901
pubmed: 26771843
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32752132
Oncotarget. 2017 May 13;8(42):71725-71735
pubmed: 29069741
J Korean Neurosurg Soc. 2020 Nov;63(6):707-716
pubmed: 32580265
Genet Mol Res. 2015 Nov 13;14(4):14253-61
pubmed: 26600483
Oncotarget. 2015 Feb 20;6(5):3452-61
pubmed: 25609202
Tumour Biol. 2016 Nov;37(11):14939-14947
pubmed: 27644254
Oncol Lett. 2017 Dec;14(6):7185-7190
pubmed: 29344150
Histopathology. 2008 Jul;53(1):73-80
pubmed: 18613926
J Biol Chem. 2015 Dec 11;290(50):30018-29
pubmed: 26487718
Cell Death Dis. 2020 Jan 23;11(1):55
pubmed: 31974361
Oncol Rep. 2017 Aug;38(2):1043-1050
pubmed: 28627681
Front Biosci. 2008 Jan 01;13:2191-202
pubmed: 17981702
Nat Genet. 2015 Aug;47(8):864-71
pubmed: 26121087
J Neurooncol. 2010 May;97(3):409-18
pubmed: 19890606
Adv Cancer Res. 2014;124:31-82
pubmed: 25287686
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119
pubmed: 35361234
Transl Oncol. 2023 Jan;27:101580
pubmed: 36327699
Curr Opin Cell Biol. 2018 Jun;52:96-104
pubmed: 29518673
Hippokratia. 2010 Oct;14(4):236-40
pubmed: 21311629
World J Gastrointest Oncol. 2021 Aug 15;13(8):799-821
pubmed: 34457187
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Cancers (Basel). 2021 Sep 09;13(18):
pubmed: 34572755
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
J Cancer. 2017 Feb 25;8(5):816-824
pubmed: 28382144
Front Immunol. 2014 Feb 12;5:56
pubmed: 24575100
Nat Rev Immunol. 2009 Oct;9(10):692-703
pubmed: 19859064
EBioMedicine. 2020 Aug;58:102931
pubmed: 32739874
J Inflamm Res. 2022 Feb 25;15:1349-1364
pubmed: 35241923
Cancer Biother Radiopharm. 2005 Oct;20(5):534-46
pubmed: 16248769
Br J Cancer. 2019 Jan;120(1):26-37
pubmed: 30413825
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820942245
pubmed: 32856542
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Cancer Immunol Immunother. 2010 Aug;59(8):1163-71
pubmed: 20333377
J Cell Physiol. 2019 May;234(5):5451-5465
pubmed: 30471116
Mod Pathol. 2021 Apr;34(4):748-757
pubmed: 33299109
Clin Cancer Res. 2021 Mar 1;27(5):1227-1235
pubmed: 33051306
Mol Cancer Ther. 2011 Jun;10(6):960-71
pubmed: 21518725
Cancer Cell. 2019 Feb 11;35(2):221-237.e8
pubmed: 30753824
Clin Cancer Res. 2021 May 15;27(10):2938-2946
pubmed: 33619171
Cancer Cell Int. 2013 Aug 16;13(1):81
pubmed: 23947693
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
J Cancer. 2018 Jun 23;9(15):2612-2624
pubmed: 30087701
Ann Diagn Pathol. 2020 Jun;46:151483
pubmed: 32143173
Oncotarget. 2017 Sep 21;8(54):93156-93167
pubmed: 29190985
J Clin Invest. 2018 Jan 2;128(1):341-358
pubmed: 29202480
Front Oncol. 2018 Jul 06;8:264
pubmed: 30035102
Biomed Res Int. 2019 Dec 17;2019:9301989
pubmed: 31950059
Genes Chromosomes Cancer. 2014 Oct;53(10):803-14
pubmed: 24898736
Cancer Chemother Pharmacol. 2018 Feb;81(2):245-253
pubmed: 29299639
J Cell Physiol. 2019 Dec;234(12):21785-21795
pubmed: 31222741
Front Oncol. 2020 Dec 14;10:581107
pubmed: 33381449
Transl Oncol. 2020 Feb;13(2):365-371
pubmed: 31887631
Acta Pharm Sin B. 2021 May;11(5):1129-1147
pubmed: 34094824
Nat Rev Clin Oncol. 2021 Jun;18(6):327-344
pubmed: 33558752
BMC Cancer. 2022 Nov 2;22(1):1124
pubmed: 36320072
Clin Cancer Res. 2019 Apr 15;25(8):2560-2574
pubmed: 30655315
Nat Commun. 2021 Jan 21;12(1):511
pubmed: 33479234
Sci Rep. 2021 Sep 22;11(1):18802
pubmed: 34552155
Pathobiology. 2020;87(3):179-192
pubmed: 32088722
Br J Cancer. 2014 Apr 15;110(8):2072-80
pubmed: 24577056
Oncotarget. 2016 May 31;7(22):31755-71
pubmed: 27145365
Biomark Res. 2022 Mar 18;10(1):12
pubmed: 35303962
Cells. 2021 Nov 26;10(12):
pubmed: 34943835
Oncol Rep. 2014 Dec;32(6):2760-8
pubmed: 25310198
Biomed Pharmacother. 2022 Feb;146:112512
pubmed: 34894519
Am J Clin Exp Immunol. 2017 Jun 15;6(4):66-75
pubmed: 28695059
Mol Cancer. 2020 Jul 17;19(1):116
pubmed: 32680511
Mol Biotechnol. 2021 Sep;63(9):849-861
pubmed: 34100183
Oncol Lett. 2017 Nov;14(5):6177-6183
pubmed: 29113264
FEBS J. 2021 Dec;288(24):7162-7182
pubmed: 33405316
Eur J Cancer. 2021 Feb;144:123-150
pubmed: 33341446
Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12640-5
pubmed: 15314238
J Clin Med. 2018 Jul 10;7(7):
pubmed: 29996538
World J Gastroenterol. 2015 Feb 14;21(6):1804-13
pubmed: 25684945